Shen, Tao
Hu, Xueqing http://orcid.org/0000-0002-6008-917X
Liu, Xuan
Subbiah, Vivek
Mooers, Blaine H. M. http://orcid.org/0000-0001-8181-8987
Article History
Received: 28 November 2020
Accepted: 13 May 2021
First Online: 7 June 2021
Competing interests
: Vivek Subbiah declares the following competing financial interests: Research funding/grant support for clinical trials: Roche/Genentech, Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Loxo Oncology, Medimmune, Altum, Dragonfly Therapeutics, Takeda and, National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals; Travel: Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte; Consultancy/ Advisory board: Helsinn, LOXO Oncology/Eli Lilly, R-Pharma US, INCYTE, QED Pharma, Medimmune, Novartis. Other: Medscape. The remaining authors declare no competing interests.